Genmab — Februar 2020
-
-
Bryan Garnier
GENMAB BUY | DKK1900 vs. DKK1700 Higher-than.expected 2020 OPEX guidance could be good entry point
2020 guidance has caught the consensus off the guard
Earlier lines will drive Darzalex’s growth in the coming years
Epcoritamab and GEN1046 represent the next generation
FV increased to DKK 1,900 and Buy rating reiterated -
Ser godt ud. Tror dog stadig på retracement i kommende uge. Vi har lige banked imod toppen af den opadgående trendkanal fra Oktober 2018 https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/81884_genmab_1734.JPG
-
Then, the use of daratumumab after a PD-1 or PDL-1 checkpoint blockers in solid tumors that's entirely up to Janssen. Janssen is following the field. They are looking at the Sanofi work with isatuximab and they have already said publicly that they are willing to move into solid tumors again with daratumumab, but then they will use SubQ daratumumab. And don't forget that we know of also this new HexaBody CD38 program, which will go into the clinic this year, which Genmab will drive, Asthika.
-
McJean: Den, der lever stille, lever godt :-)....og lad dig ikke snyde af Panikken
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind